jens juul holst glp-1 Holst: physician-scientist and co-discoverer of GLP-1 Medicines Promise More Than

Short-acting GLP-1RAs, such as lixisenatide, maintain robust effects on gastric emptying, whereas long-acting agents, like liraglutide and semaglutide, exhibit reduced efficacy due to continuous receptor activation

Custom Titration: The dose is gradually increased by your provider to maximize results while minimizing side effects

Maintaining hydration, eating fiber-rich foods, and staying active can significantly reduce symptoms

Beyond glycemic control, GLP-1 medications slow gastric emptying, which prolongs the sensation of fullness after eating and contributes to reduced appetite

People taking GLP-1s were somewhat more likely to develop these problems over five years than people not taking the drugs

Microdosing Semaglutide Split-dosing protocols for Ozempic and Wegovy.